Skip to main content
Cachet Pharmaceutical Co., Ltd. logo

Cachet Pharmaceutical Co., Ltd. — Investor Relations & Filings

Ticker · 002462 ISIN · CNE100000SN0 LEI · 300300CBONJS7HUOCX64 Shenzhen Stock Exchange Wholesale and retail trade
Open in API
Filings indexed 1,441 across all filing types
Latest filing 2018-01-23 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 002462

About Cachet Pharmaceutical Co., Ltd.

https://www.cachet.com.cn

Cachet Pharmaceutical Co., Ltd. specializes in the distribution and retail of pharmaceutical products and medical devices. The company operates an extensive wholesale network and a chain of retail pharmacies, providing comprehensive supply chain solutions to healthcare institutions and end-consumers. Its core operations include the procurement, storage, and logistics of western medicines, traditional Chinese medicines, and high-value medical consumables. Cachet Pharmaceutical emphasizes modern logistics management and professional pharmaceutical services, leveraging a robust distribution infrastructure to ensure the efficient delivery of healthcare products. The company also focuses on hospital supply chain integration and community-based retail services to enhance healthcare accessibility.

Recent filings

Filing Released Lang Actions
关于2018年度公司向银行申请综合授信额度的公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from 嘉事堂药业股份有限公司 regarding the company's application for a comprehensive credit line from banks for the year 2018. It details the total credit amount, the banks involved, and the authorization for the chairman to sign related legal documents. The document is short (927 characters) and serves as a formal announcement of financing activity rather than a detailed financial report or results. It does not contain financial statements or detailed analysis but focuses on the update about financing arrangements. Therefore, it fits the category of Capital/Financing Update (CAP).
2018-01-23 Chinese
关于召开2018年第一次临时股东大会的通知公告
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a detailed notice about convening the 2018 first extraordinary general meeting of shareholders for 嘉事堂药业股份有限公司. It includes information about the meeting time, location, agenda items (such as proposals for credit facilities, changes in directors and supervisors), voting procedures (including cumulative voting), registration methods, and proxy authorization forms. There is no financial data or results reported, nor is it a transcript or presentation. It is a formal announcement inviting shareholders to attend and vote on specific proposals at the meeting. This fits the definition of a Proxy Solicitation & Information Statement (PSI), which provides materials sent to shareholders to inform and request votes for meetings.
2018-01-23 Chinese
独立董事对公司第五届董事会第二十一次会议相关事项的独立意见
Board/Management Information Classification · 95% confidence The document is an independent directors' opinion on matters discussed at the 21st meeting of the 5th board of directors of 嘉事堂药业股份有限公司. It includes opinions on board candidate nomination, bank credit application, and related party transactions. The content focuses on board and governance matters rather than financial results or reports. The document is relatively short (1481 characters) and does not contain financial statements or detailed financial data. It is not an announcement of voting results but an independent opinion related to board decisions. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or opinions related to the company's board or senior management.
2018-01-23 Chinese
详式权益变动报告书
Major Shareholding Notification Classification · 95% confidence The document is titled '嘉事堂药业股份有限公司详式权益变动报告书', which translates to 'Detailed Equity Change Report of Jia Shi Tang Pharmaceutical Co., Ltd.' It is a detailed report about the change in equity ownership, specifically the transfer of 100% state-owned property rights from one entity to another, involving major shareholders and their shareholding structures. The document includes sections on the equity change situation, purpose, method, funding source, future plans, impact analysis, and related transactions. It is a comprehensive disclosure about a significant change in shareholding and control of the company. This matches the definition of a 'Major Shareholding Notification' (Code: MRQ), which covers notifications of changes in significant share ownership levels (crossing thresholds). The document is lengthy (15,000 characters), contains detailed information about shareholding changes, and is not merely an announcement or a proxy solicitation. Therefore, the correct classification is MRQ with high confidence.
2018-01-08 Chinese
关于股东权益变动暨实际控制人变更的提示性公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding a change in shareholder equity and actual control of the company 嘉事堂药业股份有限公司. It details the transfer of ownership from one controlling entity to another, including specifics about shareholding percentages and control changes. The document does not contain financial statements or detailed financial performance data, nor is it a transcript, presentation, or report. It is an announcement about a significant change in major shareholding and control structure. Therefore, it fits the category of Major Shareholding Notification (MRQ). The document length is short (1717 characters), and it is not merely announcing the publication of a report but providing substantive information about the shareholding change.
2018-01-04 Chinese
简式权益变动报告书
Major Shareholding Notification Classification · 100% confidence The document is titled as a "简式权益变动报告书" which translates to a "Simplified Equity Change Report." It details the change in shareholding by the information disclosure obligor, the Communist Youth League Central Committee, regarding its indirect shareholding in Jia Shi Tang Pharmaceutical Co., Ltd. The document includes sections on the purpose of the equity change, shareholding before and after the change, the method of equity change (state-owned property transfer), and declarations about the absence of other share transactions. It also references relevant Chinese securities laws and regulations governing equity changes and disclosures. The document is a formal notification of a change in major shareholding and does not contain financial statements or earnings data. It is not an annual or interim report, nor an earnings release or management discussion. It is a regulatory disclosure about a significant shareholding change, fitting the definition of a Major Shareholding Notification (MRQ). The document length (6163 characters) and detailed content support this classification rather than a brief announcement or a report publication announcement.
2018-01-04 Chinese

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.